FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:1074-1076 March 9, 2006 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Chang, T.-T. Related Article by Lai, C.-L. PubMed Citation

Chronic infection with hepatitis B virus (HBV) accounts for an enormous burden of disease worldwide, including up to half of all cases of cirrhosis, end-stage liver disease, and hepatocellular carcinoma.¹ With the development of a safe and effective vaccine in the early 1980s, hepatitis B became a preventable disease. Routine HBV vaccination of newborns in Taiwan and China, areas of the world with high rates of hepatitis B, was followed by significant declines in rates of chronic hepatitis B and hepatocellular carcinoma.² In the United States, where the disease is uncommon, the incidence of new cases is currently 75 percent . . . [Full Text of this Article]

Source Information

From the Liver Disease Research Branch, Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Md.

This article has been cited by other articles:

• Llovet, J. M., Lok, A. (2008). Hepatitis B Virus Genotype and Mutants: Risk Factors for Hepatocellular Carcinoma. JNCI J Natl Cancer Inst 100: 1121-1123 [Full Text]  
• Tonks, A. (2006). What's new in the other general journals.. BMJ 332: 654-655 [Full Text]  
• (2006). Entecavir for Chronic Hepatitis B. JWatch General 2006: 1-1 [Full Text]